United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...

A biotechnology company in Research Triangle Park has taken a major step to develop a new option for patients in need of a ...

It is hard to get excited after looking at United Therapeutics' (NASDAQ:UTHR) recent performance, when its stock ...

UTHR currently has a forward P/E ratio of 12.63, while ZTS has a forward P/E of 27.56. We also note that UTHR has a PEG ratio of 0.92. This metric is used similarly to the famous P/E ratio, but the ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...

The final step today is to look at a stock that meets our ESP qualifications. United Therapeutics (UTHR) earns a #2 (Buy) 14 days from its next quarterly earnings release on February 19 ...

If PH-ILD studies translate into the real world, the market opportunity for Liquidia is enormous. Where should we expect LQDA stock to be in the next few months? Find out.